WVE vs. LYEL, SIGA, ZYME, PRAX, AVTE, SVRA, PHAR, ORIC, IRON, and GHRS
Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include Lyell Immunopharma (LYEL), SIGA Technologies (SIGA), Zymeworks (ZYME), Praxis Precision Medicines (PRAX), Aerovate Therapeutics (AVTE), Savara (SVRA), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), Disc Medicine (IRON), and GH Research (GHRS). These companies are all part of the "pharmaceutical preparations" industry.
Wave Life Sciences (NASDAQ:WVE) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings.
Wave Life Sciences received 333 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 67.25% of users gave Wave Life Sciences an outperform vote while only 54.55% of users gave Lyell Immunopharma an outperform vote.
Wave Life Sciences has a net margin of -50.76% compared to Lyell Immunopharma's net margin of -180,486.14%. Wave Life Sciences' return on equity of 0.00% beat Lyell Immunopharma's return on equity.
Wave Life Sciences presently has a consensus price target of $10.14, suggesting a potential upside of 117.66%. Lyell Immunopharma has a consensus price target of $5.50, suggesting a potential upside of 153.46%. Given Lyell Immunopharma's higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Wave Life Sciences.
89.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 31.1% of Wave Life Sciences shares are owned by company insiders. Comparatively, 24.0% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Wave Life Sciences had 3 more articles in the media than Lyell Immunopharma. MarketBeat recorded 4 mentions for Wave Life Sciences and 1 mentions for Lyell Immunopharma. Wave Life Sciences' average media sentiment score of 0.45 beat Lyell Immunopharma's score of 0.00 indicating that Wave Life Sciences is being referred to more favorably in the media.
Wave Life Sciences has a beta of -1.12, meaning that its share price is 212% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.56, meaning that its share price is 156% less volatile than the S&P 500.
Wave Life Sciences has higher revenue and earnings than Lyell Immunopharma. Wave Life Sciences is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Wave Life Sciences beats Lyell Immunopharma on 14 of the 18 factors compared between the two stocks.
Get Wave Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Wave Life Sciences Competitors List
Related Companies and Tools
